JB Chemicals & Pharmaceuticals Limited has informed the Exchange about additional investment in wholly-owned subsidiary
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JB Chemicals & Pharmaceuticals' board, at its meeting on January 7, 2026, approved an additional investment of up to ~Rs. 18 crores in its wholly-owned Dubai-based subsidiary, Unique Pharmaceutical Laboratories FZE (UPL FZE). The investment will be made in cash, likely within three months in one or more tranches, and will be used for the subsidiary's operational requirements. UPL FZE, incorporated in December 2013 in the Jebel Ali Free Zone, is engaged in medicines trading and reported a modest revenue of AED 627,639 in FY24-25, with no revenue in the prior two years. The transaction is at arm's length and the subsidiary will continue to be wholly-owned.
The Rs. 18 crore infusion is a small amount relative to JB Chemicals' overall size and is unlikely to materially affect the stock price. It reflects routine operational funding for the Dubai trading arm rather than a significant strategic expansion.